JP2021500026A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500026A5 JP2021500026A5 JP2020521889A JP2020521889A JP2021500026A5 JP 2021500026 A5 JP2021500026 A5 JP 2021500026A5 JP 2020521889 A JP2020521889 A JP 2020521889A JP 2020521889 A JP2020521889 A JP 2020521889A JP 2021500026 A5 JP2021500026 A5 JP 2021500026A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- seq
- inhibitor molecule
- lipid
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023132823A JP2023175693A (ja) | 2017-10-18 | 2023-08-17 | βカテニン核酸阻害剤分子 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762573999P | 2017-10-18 | 2017-10-18 | |
| US62/573,999 | 2017-10-18 | ||
| PCT/US2018/056317 WO2019079472A1 (en) | 2017-10-18 | 2018-10-17 | BETA-CATENIN NUCLEIC ACID INHIBITOR MOLECULE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023132823A Division JP2023175693A (ja) | 2017-10-18 | 2023-08-17 | βカテニン核酸阻害剤分子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021500026A JP2021500026A (ja) | 2021-01-07 |
| JP2021500026A5 true JP2021500026A5 (enExample) | 2021-11-25 |
Family
ID=66173850
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521889A Ceased JP2021500026A (ja) | 2017-10-18 | 2018-10-17 | βカテニン核酸阻害剤分子 |
| JP2023132823A Pending JP2023175693A (ja) | 2017-10-18 | 2023-08-17 | βカテニン核酸阻害剤分子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023132823A Pending JP2023175693A (ja) | 2017-10-18 | 2023-08-17 | βカテニン核酸阻害剤分子 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11008571B2 (enExample) |
| EP (1) | EP3672980A4 (enExample) |
| JP (2) | JP2021500026A (enExample) |
| KR (1) | KR20200078538A (enExample) |
| CN (1) | CN111225922B (enExample) |
| AU (1) | AU2018350983A1 (enExample) |
| BR (1) | BR112020007443A2 (enExample) |
| CA (1) | CA3076924A1 (enExample) |
| IL (1) | IL273772A (enExample) |
| MX (1) | MX2020004045A (enExample) |
| WO (1) | WO2019079472A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023122316A2 (en) * | 2021-12-23 | 2023-06-29 | Aligos Therapeutics, Inc. | SPLICE SWITCH OLIGONUCLEOTIDE (SSO) MOLECULES FOR TARGETING β-CATENIN AND USES THEREOF |
| WO2023122317A2 (en) * | 2021-12-23 | 2023-06-29 | Aligos Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES FOR TARGETING β-CATENIN AND USES THEREOF |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009336191B2 (en) * | 2008-12-18 | 2017-08-24 | Novo Nordisk A/S | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
| WO2010093788A2 (en) | 2009-02-11 | 2010-08-19 | Dicerna Pharmaceuticals, Inc. | Multiplex dicer substrate rna interference molecules having joining sequences |
| ES2734743T3 (es) * | 2010-07-06 | 2019-12-11 | Dicerna Pharmaceuticals Inc | Métodos y composiciones para la inhibición específica de beta-catenina por RNA bicatenario |
| CN103068980B (zh) * | 2010-08-02 | 2017-04-05 | 瑟纳治疗公司 | 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制 |
| FI3366775T4 (fi) * | 2011-11-18 | 2025-11-14 | Alnylam Pharmaceuticals Inc | Modifioituja rnai-agensseja |
| EP3865576A1 (en) * | 2014-12-15 | 2021-08-18 | Dicerna Pharmaceuticals, Inc. | Ligand-modified double-stranded nucleic acids |
| CA3017963A1 (en) | 2016-03-16 | 2017-09-21 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the treatment of a beta-catenin-associated disease or disorder |
-
2018
- 2018-10-17 MX MX2020004045A patent/MX2020004045A/es unknown
- 2018-10-17 CN CN201880067973.3A patent/CN111225922B/zh not_active Expired - Fee Related
- 2018-10-17 CA CA3076924A patent/CA3076924A1/en active Pending
- 2018-10-17 KR KR1020207013634A patent/KR20200078538A/ko not_active Ceased
- 2018-10-17 WO PCT/US2018/056317 patent/WO2019079472A1/en not_active Ceased
- 2018-10-17 US US16/754,452 patent/US11008571B2/en not_active Expired - Fee Related
- 2018-10-17 BR BR112020007443-8A patent/BR112020007443A2/pt unknown
- 2018-10-17 JP JP2020521889A patent/JP2021500026A/ja not_active Ceased
- 2018-10-17 AU AU2018350983A patent/AU2018350983A1/en not_active Abandoned
- 2018-10-17 EP EP18867422.0A patent/EP3672980A4/en not_active Withdrawn
-
2020
- 2020-04-02 IL IL273772A patent/IL273772A/en unknown
-
2021
- 2021-04-15 US US17/231,696 patent/US20210238603A1/en not_active Abandoned
-
2023
- 2023-08-17 JP JP2023132823A patent/JP2023175693A/ja active Pending